Translational Development Acquisition Corp.

Translational Development Acquisition Corp. (Nasdaq: TDAC) is a blank-check company focused on the life sciences and healthcare sector, targeting opportunities in translational medicine and biotech-adjacent development. The company filed a Form 10-K/A — an amendment to its annual report — with the SEC on May 11, 2026, under accession number 0001104659-26-058544, indicating a material revision to previously reported annual disclosures. TDAC has been active in the SPAC market and continues to be monitored by investors tracking life sciences deal flow. For complete filing history, sponsor details, deal status, and data analytics on TDAC, sign up for full access at SpacDesk.